Profusa (NVACW) Deferred Taxes (2023 - 2024)

Profusa posted quarterly Deferred Taxes of $13661.0 for Q1 2024, up 138.38% year-on-year from $5730.8 in Q2 2023, and up 200.0% on a QoQ basis from -$13661.0 in Q4 2023.

Profusa (NVACW) has 2 years of Deferred Taxes data on file, last reported at $13661.0 in Q1 2024.

  • For the quarter ending Q1 2024, Deferred Taxes rose 138.38% year-over-year to $13661.0; the trailing twelve-month figure through Dec 2024 stood at $13661.0 (down 41.32% YoY), and the FY2024 full-year result was $13661.0, down 41.32% from the prior year.
  • Deferred Taxes for Q1 2024 stood at $13661.0, up from -$13661.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $72537.0 in Q2 2023 and bottomed at -$35597.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -33.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -101.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -9.40 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 300,000.00
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -16.70 Mn
10 Profusa - - - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 13,661.00
Dec 31, 2023 -13,661.00
Jun 30, 2023 72,537.00
Mar 31, 2023 -35,597.00